Roberto Botelho

Showing 1-3 of 3 articles

Coronary interventions

Five-year safety and performance data of a novel third-generation novolimus-eluting bioresorbable scaffold in single de novo lesions

Verheye S, Costa R, Schofer J, Ormiston J, Maeng M, Dudek D, Skurk C, Botelho R, Costa J, Chamié D, Abizaid An, Boersma E, Abizaid A

October 18, 2019 | 10.4244/EIJ-D-18-00292

Coronary interventions

Randomised comparison of a biodegradable polymer ultra-thin sirolimus-eluting stent versus a durable polymer everolimus-eluting stent in patients with de novo native coronary artery lesions: the meriT-V trial

Abizaid A, Kedev S, Kedhi E, Talwar S, Erglis A, Hlinomaz O, Masotti M, Fath-Ordoubadi F, Lemos P, Milewski K, Botelho R, Costa R, Bangalore S

December 7, 2018 | 10.4244/EIJ-D-18-00762

Impact of post-dilation on the acute and one-year clinical outcomes of a large cohort of patients treated solely with the Absorb Bioresorbable Vascular Scaffold

Costa Jr J, Abizaid A, Bartorelli A, Whitbourn R, van Geuns R, Chevalier B, Perin M, Seth A, Botelho R, Serruys P

June 19, 2015 | 10.4244/EIJY15M05_06

1

Latest news

State of the Art on ViV-TAVI; Transseptal Punctures; Endovascular Closure and TF-TAVI; Percutaneous PVL Closure: Long-Term Outcomes; and more

October 20, 2021

STATE OF THE ART

Valve-in-valve TAVI: a practical overview

Giuseppe Tarantini et al.

October 20, 2021

TAVI in younger (<70 years old) patients: the AMTRAC registry

Guy Witberg et al.

October 22, 2021

Impact of LVOT calcification in transfemoral TAVI patients

L. Waldschmidt et al.

October 19, 2021

My Stroke Story

October 20, 2021

Impact of preprocedural biological markers on 10-year mortality in the SYNTAXES trial

Hironori Hara et al.

October 22, 2021

Serum caffeine causes adenosine-induced FFR overestimation

Hideaki Tanaka et al.

October 15, 2021

Valvular disease